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Chromium is an essential trace mineral required for 
carbohydrate and lipid metabolism in rats as well as in 
humans. Chromium deficiency can result in elevated blood 
cholesterol in addition to glucose intolerance (Mertz, 1993). 
In the United States, 50-200 ~g/day of chromium is 
recommended as the estimated safe and adequate intake for 
adults (NRC, 1989). In the late 1970s estimated mean 
chromium intake in the United States ranged from 25-89 ~/day 
(Kumpulainen et al., 1979). However, lower values have since 
been recorded using improved analytical techniques. 
According to a study by Anderson and Kozlovsky (1985), when 
self-selected diets were analyzed for chromium content, most 
of the diets contained less than 50 ~/day. Bunker et al. 
(1984) also reported similar results from their study. 
In 1966, Glinsmann and Mertz showed that in some cases of 
diabetes mellitus, chromium supplementation of 150 to 200 
~/day taken for at least three months improved glucose 
utilization. Contrary to that, Sherman et al. did not find 
improvement in the utilization of glucose with chromium 





Chromium in foods is generally decreased with processing 
(Wolf et al., 1974). Since chromium is needed for the 
metabolism of carbohydrate, foods low in chromium may deplete 
chromium from tissue stores and cause it to be excreted in 
the urine (Schroeder, 1968). Thus consumption of highly 
processed foods may result in increased excretion of chromium 
in urine as well as in depletion of body chromium stores 
(Mertz et al., 1974). The elderly are particularly at risk 
of deficiency because of their increased consumption of 
processed foods as well as their altered metabolism due to 
aging (Exton-Smith, 1972). 
Glucose tolerance declines with aging (Jackson et al., 
1982). Schroeder et al. (1962) showed that in humans, tissue 
chromium levels decreased as they grew older. Confirmation 
of this work is needed using newer analytical methods. 
According to Offenbacher (1992), chromium metabolism is 
altered in the elderly with decreased retention and increased 
urinary losses. Offenbacher and Pi-Sunyer (1980) suggested 
that some of the glucose intolerance in the elderly may be 
the result of chromium deficiency. Mertz (1993) concluded 
that severe chromium deficiency may contribute to diabetes 
and atherosclerosis in the elderly. 
In the united States, the elderly are at risk for drug-
nutrient interactions because of their excessive use of over-
the-counter (OTC) as well as prescribed medications (Roe, 
1986). Spicer et al. (1992) reported that 51cr absorption 
was significantly reduced in rats when dosed with over-the-
1 
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counter antacid or sucralfate, a medication used for ulcer 
therapy. There is a concern regarding chromium status with 
use of over-the-counter drugs. 
Davis et al. (1995) studied the effects of five over-the-
counter drugs [Turns (calcium carbonate); Maalox (aluminum 
hydroxide and magnesium hydroxide); vitamin C; aspirin; 
Bufferin; or water] on 51chromium utilization by rats. They 
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found that the aspirin group had increased absorption, tissue 
retention and urinary excretion of 51chromium. The Maalox 
group had the lowest chromium absorption, lowest retention 
and lowest urinary excretion while the group dosed with Turns 
was the next lowest among the six groups. This study showed 
that some OTC drugs, particularly antacids, reduced chromium 
status of rats. 
Drugs can affect nutritional status of the elderly 
especially when the dietary intake is marginal (Roe, 1985). 
In elderly patients, mineral depletion is the most common 
example of drug induced nutritional deficiencies (Roe, 1986). 
Unfortunately, data on drug-chromium interactions in humans 
are not available. 
The nonsteroidal antiinflammatory drugs (NSAIDs) such as 
aspirin and indomethacin (which was used in the present 
study) are commonly used for rheumatoid and osteoarthritis. 
NSAIDs produce gastric ulcers in 20% of patients, who use 
them extensively for arthritis (Uribe, 1993). These 
analgesics can cause gastrointestinal (GI) ulcers as well as 
bleeding by inhibiting endogenous prostaglandin synthesis in 
I 
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humans (Johansson et al., 1980) and in rats (Takeuchi et al., 
1986). Thus long-term intake of NSAIDs can cause iron 
deficiency anemia by inducing blood loss from the 
gastrointestinal tract. 
Gastrointestinal prostaglandins reduce and in some cases 
even prevent GI damage caused by NSAIDs (Robert, 1979). 
Prostaglandins of the E and I types have been found in 
gastric as well as intestinal mucosa (Konturek & Pawlik, 
1986; Miller, 1983). There are a few studies which suggest 
that gastrointestinal PGs have a role in absorption of 
minerals such as zinc (Song and Adham, 1978) and calcium 
(Johansson et al., 1980). 
The present study was designed to determine the effects of 
gastrointestinal prostaglandins on chromium absorption, 
tissue distribution and urinary excretion. Because chromium 
absorption in the body is very low and accurate measurement 
of chromium in biological fluids is difficult, 51chromium was 
used in this experiment. Use of a radioactive isotope of 
chromium allows the sensitive evaluation needed to determine 




Indomethacin - a nonsteroidal anti-inflammatory drug which 
inhibits prostaglandin synthesis. Used clinically for the 
treatment of arthritis. 
Misoprostol - an analogue of PGE1. Used clinically for the 
treatment of ulcers (Cytotec®). 
Vehicle - material used to administer the drug (In the 
present study, 1% Tween 80 in 0.9% saline). 
16, 16-Dimethylprostaglandin E2 (DMPGE2) - an analogue of 
PGE2. 
Prostacyclin (PGI2) - a naturally occurring prostaglandin. 
Purpose and Objectives 
The purpose of this study was to determine the effects of 
prostaglandins on chromium absorption, tissue distribution 
and urinary excretion. The following objectives were 
developed for this study: 
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1. To determine the effect of indomethacin, a blocker of 
prostaglandin synthesis, on 51cr absorption, retention and 
urinary excretion. 
2. To determine the effects of misoprostol(PGE1 analogue), 
16, 16-Dimethylprostaglandin E2 (16, 16-DMPGE2) 1 or 
prostacyclin (PGI2) on 51cr absorption, retention and 
urinary excretion in adult male rats. 
6 
Hypotheses 
The following hypotheses were developed for this study: 
1. There will be no significant effect of intraperitoneally 
injected indomethacin, a blocker of prostaglandin 
synthesis, on 51cr absorption, retention or urinary 
excretion. 
2. There will be no significant effects of intubated doses 
of misoprostol, 16, 16-Dimethylprostaglandin E2, or 
prostacyclin on 51cr absorption, retention or urinary 
excretion. 
Assumption 
It is assumed that intraperitoneally injected indomethacin 
(5 mg/kg body wt), a prostaglandin inhibitor, has completely 
blocked the synthesis of endogenous prostaglandins. 
Limitations 
1. The bioavailability of 51cr from CrCl3 may be different 
from dietary chromium. 
2. Because of the use of animal models in this experiment, 
the results cannot be extrapolated directly to humans. 
_..... 
CHAPTER II 
REVIEW OF LITERATURE 
Chromium 
In 1959, chromium was found to be an essential trace 
mineral required for the utilization of glucose in rats 
(Schwarz and Mertz, 1959). When laboratory rats were fed a 
chromium deficient diet, they developed a diabetes-like 
condition. The condition was reversed when chromium was 
reintroduced (Schroeder, 1966). In addition to impaired 
glucose tolerance, severe chromium deficiency also caused 
stunted growth, high mortality in young animals, shortened 
life span and increased incidence of aortic atherosclerosis 
in laboratory animals (Hambidge, 1978). 
Jeejeebhoy et al. in 1977 found that trivalent chromium was 
necessary for carbohydrate metabolism in humans, as well as 
in animals, when diabetes-like symptoms were reversed with 
the administration of chromium in a 30-year old patient 
receiving total parenteral nutrition. Many of the above 
mentioned chromium deficiency symptoms also are common in 
humans (Jeejeebhoy, 1977). 
In the United States, 50-200 ~g/day of chromium is 
recommended as the estimated safe and adequate intake for 
adults (NRC, 1989). Anderson and Kozlovsky (1985), reported 
that when self-selected diets were analyzed for chromium 





Chromium in foods generally is decreased with processing 
(Wolf et al., 1974). The elderly are particularly at risk of 
deficiency because of their increased consumption of 
processed food as well as their altered metabolism due to 
aging. 
Hopkins et al. (1968) showed improvement in glucose 
tolerance in children with protein-calorie malnutrition with 
the introduction of chromium. Gurson and Saner (1971) 
supported this finding. 
There is controversy about improved glucose utilization 
with chromium supplementation in some cases of diabetes. 
According to Glinsmann and Mertz (1966), in some cases of 
diabetes mellitus including juvenile and maturity onset, 
chromium supplementation improved glucose utilization. But, 
according to Sherman et al., individuals with diabetes did 
not benefit from chromium supplementation of 50 ~ of 
trivalent chromium three times daily taken for 16-weeks 
(Sherman et al., 1968). 
Levine and coworkers (1968) investigated whether elderly 
subjects with abnormal glucose tolerance benefitted from 
chromium supplementation. They suggested that chromium 
supplementation improved glucose tolerance in some of the 
elderly subjects. However Doisy and colleagues (1971) did 
not find significant difference in the absorption of chromium 
between young and elderly subjects and the question of age 
effects on chromium utilization has not been resolved. 
~~~~~~~ . l 
Doisy et al. (1968) were early investigators of the 
absorption of chromium in humans. They reported that when 
CrCl3 was used, the absorption of chromium was about 1%. In 
1986, Offenbacher and coworkers (1986) reported that the net 
absorption of chromium in subjects in a metabolic unit was 
1.8%. 
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Absorption of chromium mainly depends on the form of 
chromium. Trivalent chromium is not as well absorbed as is 
hexavalent chromium, but trivalent chromium is more prevalent 
in foods (Mertz et al., 1974). Absorption of chromium is 
greatest in the jejunum (Chen et al., 1973). Chromium is 
also absorbed in the ileum and duodenum, the other two 
sections of the small intestine (Chen et al., 1973). 
Absorption of chromium is influenced by various factors. 
Chen et al. (1973) studied the effects of chelating agents 
such as oxalate and phytate on chromium. Oxalate signifi-
cantly increased chromium absorption. They suggested that 
oxalate may chelate with chromium and prevent it from 
undergoing elation. Formation of soluble complexes in the 
small intestine may improve the absorption of chromium. 
Phytate significantly decreased chromium absorption. Chen 
and coworkers suggested, that by binding chromium and forming 
insoluble complexes, phytate may have reduced the 
availability of chromium (Chen et al., 1973). 
Hahn and Evans (1975) suggested that minerals such as 
chromium and zinc may share a common absorption pathway in 
the intestine. In zinc deficient rats, absorption and 
1 
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intestinal content of the chromium increased. Also, chromium 
blocked the absorption of zinc and reduced intestinal zinc 
content. When zinc was reintroduced orally, enhancement of 
chromium absorption was stopped in those rats. 
Chromium absorption, like the absorption of other minerals 
including iron, depends on prior chromium intake. In a study 
reported by Anderson and Kozlovsky (1985), chromium 
absorption in humans was inversely related to dietary 
chromium intake. At a dietary chromium intake of 10 ~g, 
absorption was approximately 2%; as intake increased to 40 
~, chromium absorption decreased to 0.5%. 
Absorbed chromium is excreted mainly via the kidneys 
(Mertz, 1969). Very little is lost in hair, perspiration or 
bile. Urinary chromium reflects recent chromium intake and 
is considered a good indicator of the amount of chromium 
absorbed (Anderson and Kozlovsky, 1985). 
Prostaglandins 
Prostaglandins (PGs) are a group of 20-carbon oxygenated 
fatty acids that are present in most mammalian cells and 
tissues (Robert, 1979). Prostaglandins were discovered in 
the early 1930's in human seminal fluid, where they were 
found in high concentration (Miller, 1983). 
Gastrointestinal (GI) mucosal cells also have a relatively 
large quantity of PGs (Robert, 1979). Prostaglandins of E 
and I types have been found in gastric as well as intestinal 
mucosa and, following stimulation, are secreted into the 
__ ...1. 
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lumen (Konturek and Pawlik, 1986; Miller, 1983). They affect 
a number of gastric as well as intestinal functions (Robert, 
1979). They show vasodilation activity, specifically in 
gastric mucosa. Both PGE2 and PGI2 are very potent 
gastroprotective prostaglandins (Bennett, 1989). 
The mechanism by which PGs protect GI mucosa is still not 
fully understood. One of the functions of PGs, cyto-
protection, involves protection of the GI tract against 
damage caused by various ulcer causing and necrotizing agents 
(Lacy, 1985). The dose at which PGs exhibit cytoprotective 
property is called the cytoprotective dose. Although many 
prostaglandins have cytoprotective properties, their 
potencies vary (Robert, 1979). For a potent prostaglandin, 
the cytoprotective dose is much lower than that of the less 
potent prostaglandin. 
Certain PGs, such as PGs of E type, which possess 
cytoprotective properties even when given in very low doses, 
can protect the GI tract against damage (Miller, 1983). The 
cytoprotective property exhibited by PGs is different from 
the antisecretory property (Robert, 1979). The dose at which 
prostaglandins inhibit gastric acid secretion, as a reaction 
to the substances which produce gastric damage, is called the 
antisecretory dose (Robert et al., 1979). According to 
Robert (1979), some PGs showed cytoprotective properties with 
even as little as 1/100th of the antisecretory dose. 
Mucus secretion is one of the other important mechanisms by 
which PGs protect GI mucosa. Some studies report that PGs 
-- _ _j_ 
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and their analogues such as 16, 16-Dimethylprostaglandin E2 
(16, 16-DMPGE2) stimulate the release of mucus into gastric 
juice in animals (Bolton and Cohen, 1978; Tao and Wilson, 
1984). 
Several other mechanisms have been proposed for 
gastrointestinal mucosal defense. Stimulation of mucus and 
alkaline secretion, stimulation of mucosal growth, 
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stabilization of lysosomal enzymes, and inhibition of gastric 
acid secretion are other possible actions (Konturek and 
Pawlik, 1986; Miller, 1983). Another theory is that 
prostaglandins such as the A, E and I types may protect 
against mucosal damage by increasing mucosal blood flow 
(Miller, 1983). But, some researchers have suggested that a 
cytoprotective prostaglandin such as 16, 16-DMPGE2 does not 
increase gastric mucosal blood flow even in a cytoprotective 
dose (Jacobson, 1985) 
Synthesis of PGs from membrane phospholipids can be 
stimulated by various factors such as neural or hormonal 
stimulation, neurotransmitters or hyperosmolar solutions 
(Konturek and Pawlik, 1986). Under physiological conditions, 
mechanical strain such as stretching a blood vessel or 
contraction of the intestine can increase PG formation. 
Tissue injuries may be another cause of PG formation 
(Konturek and Pawlik, 1986). 
Nonsteroidal antiinflammatory drugs (NSAIDs) are potent 
inhibitors of prostaglandins. They can produce gastric 
damage including ulcers in animals and humans. But 
_ _._ 
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supplemental prostaglandins even at very low doses 
(nonantisecretory doses) are useful in preventing or reducing 
NSAID induced mucosal damage in animals and humans (Wilson, 
1986). Arthritic patients on long-term treatment with NSAIDs 
are often supplemented by prostaglandins or their analogues. 
Indomethacin 
According to Graham et al., 20% of patients who use NSAIDs 
regularly develop gastroduodenal ulcers (Graham et al., 
1988). Indomethacin is a NSAID which inhibits the synthesis 
of prostaglandins. By blocking the synthesis of 
prostaglandins, NSAIDs induce gastrointestinal mucosal damage 
and thereby cause gastrointestinal ulcers in experimental 
animals (Whittle, 1976) and humans (Johansson et al., 1980). 
Indomethacin, a very potent NSAID, produces intestinal 
lesions at 7.5 mg/kg body wt in rats (Robert, 1979). 
Takeuchi et al. (1986) found that 5 mg/kg indomethacin 
reduced PGs by 80-90% in gastric mucosa 30 minutes after 
administration without the mucosal damage. 
Because PG's protect the GI mucosa, ulcer patients may 
benefit from the administration of PG's prior to NSAIDs (Yik 
et al., 1982). Johansson et al. (1980) reported that 1 mg of 
PGE2 taken orally three times daily with indomethacin 
treatment reduced GI bleeding in patients with rheumatic 
diseases. 
van Kolfschoten et al. (1983) reported that PGE2 can 
protect the stomach even when a high concentration of acid is 
....... 
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present. They also showed that there was a small but not 
significant increase in bicarbonate secretion, which suggests 
that bicarbonate secretion may not be the important factor in 
mucosal protection. Van Kolfschoten and coworkers therefore 
suggested that there may be a mechanism to protect the 
gastric mucosa other than inhibition of gastric acid 
secretion. 
Using two different doses of various NSAIDs in humans, 
including aspirin, ibuprofen, indomethacin and naproxen, 
Lanza et al. (1979) investigated whether the effects on the 
gastric mucosa were dose dependent. They reported that 
severe gastric injury was caused by aspirin, by both doses of 
indomethacin and by the higher dose of naproxen. Damage 
caused by 100 and 150 mg/day of indomethacin appeared to be 
lower but not significantly different from damage caused by 
3600 mg of aspirin. Lesser damage occurred with the lower 
dose of naproxen, and with both doses of ibuprofen and 
placebo. 
When gastric mucosal tissue of rats was pretreated with 
local application of exogenous PGs or with mild irritants 
such as 20% ethanol or 5% NaCl, mild damage to the gastric 
mucosa occurred. But, this pretreatment protected gastric 
mucosa against subsequent application of necrotizing agents. 
The protection against mucosal damage may have been due to 
increases in the synthesis of endogenous prostaglandins. 
This is called adaptive cytoprotection (Konturek et al., 
1982; Jacobson, 1986). In one of the studies, aspirin, given 
=:==::......._~~- - ---- __j_ 
either orally or subcutaneously, appeared to be 
cytoprotective in rats and prevented the intestinal lesions 
caused by indomethacin, a stronger NSAID than aspirin 
(Robert, 1979). 
Misoprostol 
Misoprostol is a synthetic analogue of prostaglandin E1. 
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Like most of the prostaglandins, misoprostol has both 
antisecretory and cytoprotective effects (Silverstein et al., 
1986). Misoprostol showed cytoprotective effects against 
gastrointestinal injury caused by ethanol, hydrochloric acid, 
sodium hydroxide, hypertonic saline and taurocholate as well 
as against damage from NSAIDs like aspirin and indomethacin 
(Robert et al., 1979). 
According to Dajani and Nissen, 50 ~g q.i.d. (four times a 
day) misoprostol significantly inhibited gastric 
microbleeding caused by 975 mg q.i.d. aspirin in humans. 
Misoprostol also significantly reduced acid and chloride 
secretion at 50 ~g q.i.d. (Dajani and Nissen, 1985). 
Misoprostol is known for its effectiveness in preventing 
and, in some cases, even promoting healing of gastric as well 
as duodenal ulcers in humans (Agrawal and Dajani 1990; Brand 
et al., 1985 and Graham et al., 1988). Jaszewski and 
coworkers (1992) reported that 200 ~g of misoprostol, four 
times daily, significantly increased the rate of healing of 
NSAID induced gastric ulcers in humans. 
-- - ______._ 
Bauer et al. (1986) compared three different doses (50, 
100, and 200 ~/kg body wt) of misoprostol with cimetidine 
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and sucralfate (SO, 100 and 200 mg/kg) for mucosal protective 
properties in rats. They studied these drugs in five 
different ulcer-promoting models (aspirin, indomethacin, 
stress, sodium taurocholate and ethanol). Sucralfate did not 
show consistent protective effects in the five ulcer models. 
Cimetidine showed positive effects in some of those models, 
but not in all while misoprostol showed protective effects in 
all models. They reported that misoprostol, even in the low 
dose of 50 ~g/kg, showed gastric mucosal protection in rats. 
Prostaglandins may enhance gastric defense mechanisms. 
When given intravenously to animals, misoprostol is a very 
potent inhibitor of gastric acid secretion (Dajani et al., 
1976). Other proposed defense mechanisms of misoprostol 
include prevention of gastric mucosal barrier disruption, 
stimulation of mucus secretion, stimulation of alkaline 
secretion, and enhancement of blood flow (Miller, 1983). 
Bauer could not demonstrate that misoprostol significantly 
increased gastric mucosal blood flow (Bauer, 1985). However, 
other studies showed that there was an increase in mucosal 
blood flow which contributed to the cytoprotective property 
of misoprostol (Brand et al., 1985; Dajani and Nissen, 1985; 
Cheung, 1980; Larsen et al., 1981). 
To evaluate the gastric mucosal protective properties of 
misoprostol, Silverstein et al. (1986) studied whether a 
clinical dose of misoprostol was sufficient to protect the 
~~~~~-~"·~= ~ 
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gastric mucosa of humans against peptic ulcer caused by 
aspirin. They reported that misoprostol did protect the 
gastric mucosa from the damaging effects of aspirin. 
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Cohen et al. (1983) reported that low doses of misoprostol 
were effective in humans in reducing GI bleeding which was 
caused by aspirin. In agreement with this finding, Hunt et 
al. (1983) reported that significant reductions in aspirin-
induced gastric bleeding and in gastric acid secretion were 
observed when people were treated with a dose of 50 ~g of 
misoprostol. 
Various studies of misoprostol show that this synthetic 
analogue of PGE1 is a drug with cytoprotective and 
antisecretory effects which can be used for treatment of 
aspirin induced mucosal damage. Also misoprostol did not 
interfere with the antirheumatic activity of NSAIDs (Agrawal 
and Dajani, 1990). This suggests that misoprostol may be 
therapeutically used for the treatment of NSAID-induced GI 
damage. 
16, 16-Dimethyl prostaglandin E2 (DMPGE2) 
A synthetic analogue of endogenous PGE2, 16, 16-Dimethyl 
PGE2 (DMPGE2) is a potent antiulcer drug (Robert, 1979). 
This analogue of PGE2 is effective in preventing indomethacin 
induced GI bleeding (Johansson et al., 1980). 
Kauffman and coworkers suggested that DMPGE2 has the 
ability to stimulate bicarbonate secretion (one of the 




topically to canine mucosa (Kauffman et al., 1980). Kuo et 
al. reported that stimulation of bicarbonate secretion by 16, 
16-DMPGE2 in dogs is not a direct effect of the prostaglandin 
on mucosal cells (Kuo et al., 1983). 
One proposed mechanism, that PGs protect mucosal damage by 
increasing mucosal blood flow, is controversial (Miller, 
1983). According to Arakawa and coworkers (1989), although 
16, 16-DMPGE2 given at 5 ~/kg intragastrically, in rats 
prevented mucosal damage caused by 20 mg/kg indomethacin, it 
did not have any effect on the mucosal blood flow. Some 
researchers likewise reported that 16, 16-DMPGE2 did not 
increase gastric mucosal blood flow even in a cytoprotective 
dose (Jacobson, 1985). 
Various factors affect endogenous PG synthesis. According 
to Bode et al. (1988), alcohol affected PG synthesis in rats. 
They suggested that chronic ingestion of alcohol inhibited PG 
synthesis and thereby caused gastric mucosal damage in rats. 
According to Tarnawski et al. (1985), 16, 16-DMPGE2 protected 
the gastric mucosa against ethanol-induced lesions. 
Gilbert et al. (1984) reported that in healthy individuals 
pretreatment with prostaglandin prevented severe gastric 
mucosal injury after a single dose of aspirin. One milligram 
of prostaglandin E2 given orally four times daily before 
aspirin ingestion prevented increased fecal blood loss in 
healthy individuals. Yik et al. (1982) observed a similar 
result with a lower dose of 0.5 mg of PGE2 four times daily. 
--~ 
Kollberg and Slezak (1982) suggested that in addition to 
prevention of ulcers, PGE2 can be used to speed up the 
healing process of duodenal ulcers. Patients treated with 
PGE2, 0.5 mg 3 times daily and 1 mg at night, had 
significantly more healed ulcers than those in the placebo 
group (Kollberg and Slezak, 1982). 
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According to Miller et al. (1983), the oral antisecretory 
dose of DMPGE2 for dogs is 50 ~/kg body wt. Thus, DMPGE2 is 
an effective antiulcer drug which has cytoprotective and 
antisecretory properties. 
Prostacyclin 
Prostacyclin (PGI2) is found in large quantities in the 
gastric mucosa. Prostaglandins of the I type as well as the 
E type are potent vasodilators (Konturek and Pawlik, 1986). 
PGI2 also is a potent inhibitor of platelet aggregation 
(Kauffman et al., 1979). In a few studies, PGI2 had 
cytoprotective as well as anti-ulcerogenic properties in rats 
(Balint & Varro, 1989; Mozsik et al., 1989). 
Mozsik et al. (1991) reported that prostacyclin did not 
have cytoprotective and mucosal protective properties in 
surgically vagotomized rats indicating that an intact vagus 
nerve is required for the development of gastric 
cytoprotection. Prostacyclin (PGI2) decreased gastric acid 
secretion in humans as well as animals (Isenberg, 1985). 
Mozsik et al. (1989) studied the effect of PGI2 on ethanol 
induced mucosal damage in rats. They reported that given 
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intragastrically 5 ~ prostacyclin/kg body weight was 100% 
cytoprotective in rats. 
PGI2 was several times more potent than PGE2 in inhibiting 
acid secretion in dogs when given intravenously. But when 
given intraarterially, PGE2 was a more potent inhibitor than 
PGI2 (Walus et al., 1980). Whittle et al. (1978) supported 
this finding. They also found that prostacyclin was a more 
potent gastric acid inhibitor than PGE2 in rats. 
During the development of gastric ulceration, the 
endogenous PGI2 content decreased markedly depending on the 
degree of ulceration. This finding suggests that endogenous 
PGI2 is one of the protective agents in gastric mucosa of 
animals as well as humans (Balint and Varro, 1989). Thus 




MATERIALS AND METHODS 
Experimental Design 
Forty-eight male Sprague Dawley rats (Sasco, Inc., Omaha, 
NE) were maintained on AIN-93G semipurified diet (Reeves et 
al., 1993) with no dietary variables for an average of 3 
weeks (Table 1). The animals weighed 188±3 grams at the end 
of the diet period. The animals were deprived of food for 12 
hours prior to the experiment but they had free access to 
distilled drinking water during that period. The animals 
were randomly assigned to 8 groups in a 2x4 factorial 
experiment. 
Treatment Protocol 
In this experiment each rat was first injected 
intraperitoneally with a dose of indomethacin or placebo. 
Thirty minutes later rats were intubated and dosed with one 
of four treatments (Figure 1). Thus twenty-four rats were 
injected intraperitoneally with 5 mg indomethacin/kg body wt 
suspended in 0.5% Tween 80 in 0.9% saline while the other 24 
rats were injected with an equivalent volume of 0.5% Tween 80 
in 0.9% saline (placebo). 
All drugs for intubation were solubilized in small volumes 
of 95% ethanol and suspended in 1% Tween 80 in 0.9% saline. 
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minutes after the indomethacin injection, the animals were 
intubated and dosed with one of four different treatments. 
Treatments were 50 ~/kg body wt misoprostol (PGE1 analogue), 
7.5 ~g/kg body wt of 16, 16-Dimethyl PGE2 (16, 16-DMPGE2, a 
PGE2 analogue), 20 ~/kg body wt of prostacyclin (PGI2) or 
control (the suspension used for other drugs). Immediately 
after intubation, the rats were given an oral dose of 100 ~Ci 
of 5lcrC13 by micropipette. 
Drugs 
Drugs used were indomethacin (Sigma Chemical Co., St. 
Louis, MO), misoprostol (G.D. Searle & co., Chicago, IL), 16, 
16-DMPGE2 (Sigma Chemical Co., St.Louis, MO) and prostacyclin 
(Sigma Chemical Co., St. Louis, MO). The 5lcrCl3 was 
obtained in 0.2 M HCl (New England Nuclear, Boston, MA). 
Indomethacin was suspended in 0.9% saline containing 0.5% 
Tween 80 (Sigma Chemical co., St. Louis, MO) before 
injection. Misoprostol, 16, 16-DMPGE2, and prostacyclin were 
solubilized in 95% ethanol and diluted with a suspension of 
1% Tween 80 in 0.9% saline. Each drug was prepared just 
before use. 
Drug Preparation 
Indomethacin for intraperitoneal injection was prepared by 
adding 20 mg of indomethacin to 4.0 ml of 0.9% saline 
containing 0.5% Tween 80. The drug suspension was mixed with 
a vortex mixer for 15 seconds. The animals were then 
_j_ 
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injected with 5 mg/kg body weight of the indomethacin 
suspension. Preparation of the placebo was identical except 
no indomethacin was added. 
The principal diluent for all intubated drugs was a 
suspension of 1% Tween 80 in 0.9% saline. Ethanol 
concentrations were kept below 2.2% for all drugs but varied 
somewhat due to differences in solubility. The control was 
prepared by adding 2.2% of 95% ethanol to the 1% Tween 80 
suspension in 0.9% saline used for the other drugs. 
Misoprostol was prepared by adding 20 ~ of ethanol to 100 
~ of ground tablet. This was followed by 4.0 ml of 1% Tween 
80 in 0.9% saline which diluted the misoprostol to a final 
concentration of 25 ~/ml in 1% Tween 80 in 0.9% saline. The 
rats were given 50 ~/kg body wt of suspended misoprostol via 
gastric intubation. 
To prepare the 16, 16-Dimethylprostagladin E2 (16, 16 
DMPGE2) 1 which was received as 1 mg in 100 ~of methyl 
acetate, 100 ~1 of 95% ethanol was added to make stock 
solution 1. One ml of 1% Tween 80 in 0.9% saline was added 
to 25 ~ of stock solution 1 to make solution 2. Twenty-five 
microliters of solution 2 was further diluted with 2 ml of 1% 
Tween 80 in 0.9% saline producing the final concentration of 
1.5 ~g/ml. The rats were given 7.5 ~g/kg body wt of 
suspended 16, 16-DMPGE2 via gastric intubation. 
Prostacyclin, which was given at 20 ~/kg body wt, was 
prepared by adding 200 ~1 of ethanol to 1 mg PGI2 (stock 
solution 1)· To 25 ~of stock solution 1, 275 ~1 of ethanol 
_----1... 
and 12.2 ml of 1% Tween 80 in 0.9% saline were added 
producing the final concentration of 10 ~g/ml. 
Immediately after intubation, the rats were given an oral 
dose of 100 ~i of CrCl3 (0.18 ~ of chromium in 50 ~ of 
0.02 M HCl) by micropipette. 
Experimental Procedure 
After dosing, the animals were placed in individual 
metabolic cages for urine collection. Urine samples were 
collected at 2, 4 and 6 hours. Approximately 0.2 ml blood 
was collected from the tail at 0.25, 0.5, 1, 2 and 4 hours 
after 51cr dosing. At the 6th hour, the rats were 
anesthetized with ketamine (30 mg/kg body wt) and xylazine 
(2.2 mg/kg body wt). The animals were exsanguinated by 
cardiac puncture and blood samples were collected. Urine, 
blood and tissues including liver, kidney, spleen, heart, 
lung, testes, pancreas and bone were sampled and counted in 
the gamma counter to assess 51cr absorption, retention and 
urinary excretion. 
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Calculation of total 51cr in blood was done assuming blood 
to be 7% of body weight (Harkness and Wagner, 1983). Data 
are expressed as percent of intubated chromium dose. Samples 
of the dose were counted each day with tissue samples to 
allow correction for decay of the 51cr. 
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Statistical Methods 
Data collected were analyzed using the Statistical Analysis 
System (SAS). Square root transformations were performed on 
the data to correct for non-homogeneity of variance. The 
general linear model (GLM) procedure in SAS was used for 
analysis of variance of the transformed tissue and urine 
data. A repeated measures analysis was performed on the 
transformed blood data. Differences among means were 
identified using the least significance difference test. 
Significance level was set at 0.05. 
CHAPTER IV 
INDOMETHACIN AND PROSTAGLANDIN EFFECTS ON ABSORPTION, 
RETENTION AND URINARY EXCRETION OF 51cHROMIUM. 
S.M. Kamath, B.J. Stoecker, M.D. Whitenack, M. Smith, 
B.O. Adeleye and s. Sangiah 
ABSTRACT 
Effects of prostaglandins on absorption, tissue 
distribution and urinary excretion of 51cr from 51crC13 were 
investigated in a 2x4 factorial experiment. Forty-eight 
adult male rats were fasted overnight and injected 
intraperitoneally with indomethacin (5 mg/kg body wt) or 
placebo. Thirty minutes later rats were intubated and given 
one of four treatments: misoprostol (50 ~g/kg body wt); a 
PGE2 analogue, 16, 16-Dimethylprostaglandin E2 (7.5 ~g/kg 
body wt); prostacyclin (20 ~g/kg body wt); or control (1% 
Tween 80 suspended in 0.9% saline containing 2.2% ethanol 
used for the other drugs). Immediately after intubation, 
rats were dosed with 100 ~i 51crC13 by micropipette. Blood 
was collected from the tail at intervals after 51cr dosing. 
At the 6th hour, animals were exsanguinated by cardiac 
puncture. Indomethacin, a blocker of prostaglandin 
synthesis, significantly increased (p<0.05) 51cr in blood at 
all time periods tested except at 15 minutes. Likewise in 
tissues, indomethacin significantly increased 51cr retention. 
Urinary 51cr excretion at four and six hours was higher 
28 
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(p<O.OS) in indomethacin-treated animals than in control 
animals. The PGE2 analogue decreased 51cr absorption and 
tissue retention below control levels. Administration of a 
drug that blocks prostaglandin synthesis enhanced 51cr 
absorption while dosing with a PGE2 analogue decreased 51cr 
absorption. 
INTRODUCTION 
Chromium is an essential trace mineral required for 
carbohydrate and lipid metabolism in rats as well as humans 
(Mertz, 1993). Chromium deficiency can cause elevated blood 
cholesterol in addition to glucose intolerance (Morris et 
al., 1992). 
In the United States, 50-200 ~g/day of chromium is 
recommended as the safe and adequate intake for adults (NRC, 
1989). In the late 1970s estimated mean chromium intake in 
the United States ranged from 25-89 ~/day (Kumpulainen, 
1979). However, lower values have since been obtained using 
improved analytical techniques. Chromium content of most 
self-selected diets was reported as less than 50 ~/day 
(Anderson and Kozlovsky, 1985; Bunker et al., 1984). 
Chromium in foods generally decreases with processing (Wolf 
et al., 1974). Consumption of highly processed foods may 
cause increased excretion of chromium in urine as well as 
depletion of body chromium stores (Mertz et al., 1974). The 
elderly may be at particular risk of depletion because of 




reduced access to a variety of foods (Nordstrom, 1982) as 
well as their altered metabolism due to aging (Exton-Smith, 
1972). 
Drug-nutrient interactions are another concern in the 
elderly. Because of the extensive use of over-the-counter 
(OTC) as well as prescribed medications, the elderly are 
particularly at risk for drug-nutrient interactions (Roe, 
1986). Davis et al. (1995) showed that antacids reduced 51cr 
absorption in rats. Spicer et al. (1992) reported that 51cr 
absorption was significantly reduced in rats when dosed with 
over-the-counter antacid or with sucralfate, a medication 
used for ulcer therapy. In elderly patients, mineral 
depletion may be the most common example of drug induced 
nutritional deficiencies (Roe, 1986). Thus, there is a 
concern regarding chromium status with the use of the over-
the-counter drugs. 
On the other hand, Davis et al. (1995) showed that aspirin, 
a nonsteroidal antiinflammatory drug (NSAID), markedly 
enhanced absorption, tissue retention and urinary excretion 
of 51cr. Analgesics, including aspirin and indo-methacin, 
are used by the elderly for arthritis. 
Indomethacin, another NSAID, inhibits prostaglandin 
synthesis and, thereby, induces gastrointestinal (GI) mucosal 
damage including GI ulcers in experimental animals (Whittle, 
1976; Miller, 1983) and humans (Johansson et al., 1980). 
Prostaglandins protect the GI mucosa against NSAID-induced 
.......... 
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mucosal damage (Agrawal et al., 1986; Balint and Varro, 1989; 
Brand et al., 1985). 
The GI mucosa has a relatively large quantity of 
prostaglandins. There they affect a number of gastric as 
well as intestinal functions (Robert, 1979). The mechanism 
by which PGs protect GI mucosa is still not fully understood. 
Song and Adham (1978) reported that pretreatment with 
indomethacin decreased zinc absorption and tissue 
distribution in rats by 60%. When zinc and prostaglandin 
were administered together, tissue distribution of zinc 
increased by 70%. They suggested that an increased level of 
PGs enhanced zinc absorption in rats. However, effects of 
gastrointestinal prostaglandins on chromium have not been 
studied. 
One objective of the present study was to determine the 
effects of endogenous gastrointestinal prostaglandins on 51cr 
absorption, tissue distribution and urinary excretion. A 
second objective was to evaluate the effects on 51cr 
distribution of supplementing with various types of 
prostaglandins or analogues. 
MATERIALS AND METHODS 
Forty eight male Sprague Dawley rats (Sasco, Inc., Omaha, 
NE) were maintained on an AIN-93G semipurified diet (Reeves 
et al., 1993) with no dietary variables for an average of 3 
weeks. Animals weighed 188±3gms at the end of the diet 
period. Food was withheld from the animals for 12 hours 
. ______._ 
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prior to the experiment but they had free access to distilled 
drinking water during that period. The animals were randomly 
assigned to 8 groups in a 2x4 factorial design. 
Twenty four rats were injected intraperitoneally with 5 
mg/kg body wt indomethacin suspended in 0.5% Tween 80 in 0.9% 
saline while the other 24 rats were injected with the same 
volume of 0.5% Tween 80 suspension in 0.9% saline without 
indomethacin (placebo). Thirty minutes later the animals 
were intubated and dosed with one of four different 
treatments: Control (1% Tween 80 suspended in 2.2% ethanol 
and 0.9% saline used for the other drugs), 50 ~g/kg body wt 
misoprostol (a PGE1 analogue), 7.5 ~g/kg body wt of 16, 16-
Dimethylprostaglandin E2 (a PGE2 analogue) or 20 ~/kg body 
wt of prostacyclin (PGI2)· Immediately after intubation, the 
rats were given an oral dose of 100 ~i of 51crClJ by 
micropipette. 
Drug Preparation 
Indomethacin for intraperitoneal injection dose was 
prepared by adding 20 mg of indomethacin to 4.0 ml 0.9% 
saline containing 0.5% Tween 80. Then the animals were 
injected with 5 mg/kg body weight of the indomethacin. 
Preparation of the vehicle (placebo) was identical except no 
indomethacin was added. 
The principal diluent for all intubated drugs was a 
suspension of 1% Tween 80 in 0.9% saline. Ethanol 





somewhat due to differences in solubility. The control was 
prepared by adding 2.2% ethanol to the 1% Tween 80 suspension 
in 0.9% saline used for the other drugs. 
Misoprostol was prepared by adding 20 ~ of ethanol to 100 
~ of ground tablet and diluting in 1% Tween 80 in 0.9% 
saline. Rats were given 50 ~g/kg body wt of misoprostol by 
gastric intubation. 
The 16, 16 DMPGE2 was received as 1 mg in 100 ~1 of methyl 
acetate and was diluted with 100 ~1 of 95% ethanol. 
Immediately before gastric intubation, the PGE2 was diluted 
to a final concentration of 1.5 ~/ml in 1% Tween 80 in 0.9% 
saline. Rats were intubated with 7.5 ~/kg body wt of PGE2. 
Prostacyclin was prepared by adding 200 ~1 of ethanol to 1 
mg PGI2. The PGI2 was diluted to a final concentration of 10 
~/ml in 1% Tween 80 in 0.9% saline. Rats were intubated 
with 20 ~/kg body wt of PGI2. 
Immediately after intubation, the rats were given an oral 
dose of 100 ~i of CrCl3 (0.18 ~ of chromium in 50 ~ of 
0.02 M HCl) by micropipette. 
Experimental Procedure 
After dosing, the animals were placed in individual 
metabolic cages for urine collection. Urine samples were 
collected at 2, 4 and 6 hours. Approximately 0.2 ml blood 
was collected from the tail at intervals of 0.25, 0.5, 1, 2 
and 4 hours after 51cr dosing. At the 6th hour, the rats 
were anesthetized with ketamine (30 mg/kg body wt) and 
_j_ 
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xylazine (2.2 mg/kg body wt). The animals were exsanguinated 
by cardiac puncture and blood samples were collected. urine, 
blood and tissues including liver, kidney, spleen, heart, 
lung, testes, pancreas and bone were sampled and counted in 
the gamma counter to assess 51cr absorption, retention and 
urinary excretion. 
Calculation of total 51cr in blood was done assuming blood 
was 7% of body weight (Harkness and wagner, 1983). Data are 
expressed as percent of intubated chromium dose. Samples of 
the dose were counted each day with tissue samples to allow 
correction for decay of the 51cr. 
Statistical Analyses 
Data were analyzed as a 2x4 factorial experiment using the 
Statistical Analysis System (SAS). Square root transfor-
mations were performed on the data to correct for non-
homogeneity of variance. The general linear model (GLM) 
procedure in SAS was used for analysis of variance of the 
transformed tissue and urine data. A repeated measures 
analysis was performed on the transformed blood data. 
Differences among means were identified using the least 
significance difference test. 
RESULTS 
Blood data were analyzed beginning at 30 minutes because of 
variable absorption at 15 minutes. No interactions were 
found between the drugs and indomethacin. Therefore, their 
·- -· .. ·- -- ........., 
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effects on the absorption, tissue distribution and urinary 
excretion of Slcr are discussed separately. Overall, animals 
pretreated with indomethacin, a blocker of prostaglandin 
synthesis, had significantly higher (p<0.0003) total Slcr in 
blood than control animals (Figure 2 and Table A2 in the 
Appendix and Figure Al in the Appendix). 
When comparing the effect of drugs on 5lcr in blood (Figure 
3 and Table A2 in the Appendix) the control group had higher 
Slcr absorption than the groups which received PGEl (p<0.03) 
and PGE2 analogue (p<O.OOOl). The group dosed with PGE2 
analogue was lower (p<0.03) than all other treatment groups. 
In tissues of indomethacin pretreated animals, retention of 
5lcr was greater (p<0.03) in all tissues except lung, 
compared to the control animals (Table 2). Most of the 5lcr 
retained in tissues was in liver and kidney. 
When drugs were compared, tissue retention of 5lcr was 
reduced significantly (p<O.OS) by PGE2 analogue compared with 
all other groups in liver, kidney, spleen, testes and bone 
(Table 2). Tissue retention in control, PGEl and PGI2 groups 
was not significantly different from each other. In heart, 
the PGE2 group was significantly lower than the control and 
PGEl groups but not lower than PGI2 group. In the lung and 
pancreas, Slcr retention was not significantly affected by 
the administered prostaglandins or analogues. 
The total cumulative urinary excretion of Slcr was 
significantly higher (p<O.OS) in indomethacin-treated animals 
than in control animals (Figure 4 and Table A4 in the 
---- ·- ---~..,.,...., 
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Appendix). Urinary excretion of 51cr at 4 hours was 
developing a trend. The significance level for the effect of 
drugs on urinary excretion of 51cr was 0.09. The group 
treated with PGE2 analogue tended to be lower (p<0.09) than 
all others (Figure 5 and Table A4). 
Significantly enhanced 51cr absorption, tissue retention 
and urinary excretion seen with indomethacin pretreatment 
appear to be mediated by the inhibition of gastrointestinal 
prostaglandins; supplementary PGE2 analogue significantly 
decreased 51cr absorption and tissue retention below control 
levels. 
DISCUSSION 
The effects of prostaglandins on chromium metabolism have 
not been studied extensively. Similar to the present study, 
Davis et al. (1995) showed that by inhibiting PG synthesis, 
aspirin enhanced chromium absorption. Also, there are two 
other studies which suggest that PGs have a role in 
absorption of other minerals, such as zinc (Song and Adham, 
1978) and calcium (Johansson et al., 1980) 
Song and Adham (1978) studied the effects of PGs on zinc 
absorption in rats. They reported that by binding zinc, 
prostaglandins enhance transport of zinc across the 
intestinal mucosa. Pretreatment with indomethacin reduced 
the zinc content of the internal organs. But when indo 
-methacin and PG were given simultaneously, the zinc content 
of the internal organs was increased. They suggested that 
-~-~~ 
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increased levels of PG enhance zinc absorption. This result 
is contrary to the results of the present study, where 
indomethacin pretreatment significantly enhanced chromium 
absorption and tissue retention 
Johansson et al. (1980) suggested that prostaglandins may 
have a role in calcium metabolism in humans. When indo-
methacin was used three times daily at 25 or 50 mg doses in 
the treatment of rheumatic diseases, they found a significant 
reduction in serum calcium. This suggests that prostaglandin 
may have a role in calcium homeostasis in humans. 
For chromium, Davis et al. (1995) showed that absorption, 
tissue retention and urinary excretion of 51chromium were 
significantly higher in animals dosed orally with aspirin 
than in control animals. They suggested that aspirin, a 
nonsteroidal antiinflammatory drug, inhibits endogenous 
prostaglandin synthesis and enhances chromium absorption. 
In the present study, pretreatment of rats with 5 mg/kg 
body wt of indomethacin significantly increased chromium 
absorption, tissue retention and urinary excretion similar to 
the results reported by Davis and coworkers. Increased 51cr 
absorption and tissue retention seen in the present study 
appears to be due to prostaglandin inhibition. 
Indomethacin is a nonsteroidal antiinflammatory drug which 
is commonly prescribed for rheumatoid arthritis. Indomethacin 
produces intestinal lesions at 7.5 mg/kg body wt in rats 
(Robert, 1979). According to Takeuchi et al. (1986) 5 mg/kg 
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body wt of indomethacin reduced PGs without damaging gastric 
mucosa. 
Some studies have shown that a variety of PGs reduce GI 
side effects associated with NSAIDs including indomethacin 
treatment when taken together (Cohen et al. 1983; Johansson 
et al., 1980). This phenomenon has been called cytoprotec-
tion. Many prostaglandins have this property. 
In the present study, administration of exogenous PGE2 
significantly decreased 51cr absorption, compared to control, 
which received no exogenous prostaglandins or analogues. 
Absorption of 51cr by animals dosed with PGI2 and PGE1 was 
between control and PGE2. 
NSAIDs including indomethacin and aspirin also work by 
inhibiting cycloooxygenase activity and in turn blocking 
prostaglandin synthesis (Kauffman, 1989). For example, 
NSAIDs block the production of PGs of the E and I type in the 
gastric mucosa. 
Even though NSAIDs increase the absorption of chromium, 
they also cause gastric mucosal injury. The mechanism by 
which NSAIDs cause gastric mucosal injury is still not fully 
understood. 
In summary, enhanced 51cr absorption seen with indomethacin 
pretreatment appears to be mediated by the inhibition of 
gastrointestinal prostaglandin synthesis. These results 
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SUMMARY AND CONCLUSIONS 
Summary 
Forty-eight adult male rats were fasted overnight and 
injected intraperitoneally with indomethacin or vehicle. 
Thirty minutes later, the rats were intubated with one of 
four treatments; a PGE1 analogue, misoprostol; a PGE2 
analogue, 16, 16-Dimethyl PGE2; PGI2, prostacyclin or 
placebo. The intubated treatment was followed immediately by 
an oral dose of 51crC13. Blood, urine and tissues were 
collected and counted in the gamma counter to assess 51cr 
absorption, retention and urinary excretion. 
Indomethacin, a blocker of prostaglandin synthesis, 
significantly increased (p<O.OS) 51cr in blood at all time 
periods tested except 15 minutes. In tissues, indomethacin 
significantly increased 51cr retention. urinary 51cr 
excretion was higher (p<O.OS) in indomethacin-treated animals 
than in control animals. Overall, blocking prostaglandin 
synthesis with indomethacin increased 51cr absorption. 
Conclusions 
In this experiment, indomethacin, a nonsteroidal 
antiinflammatory drug enhanced chromium absorption. Even 
though patients who use this drug may benefit by the 




NSAIDs may cause GI damage and may ultimately cause ulcers. 
The increase in chromium absorption and tissue retention seen 
in the present study may be because of inhibiting PG 
synthesis. Supplementing with PGs or prostaglandin analogues 
to protect the GI mucosa from damage may be detrimental to 
chromium status. 
Hypotheses 
The following hypotheses were developed for this study: 
1. There will be no significant effect of intraperitoneally 
injected indomethacin, a blocker of prostaglandin 
synthesis, on Slcr absorption, retention or urinary 
excretion. 
2. There will be no significant effect of intubated doses 
of misoprostol, 16, 16-Dimethylprostaglandin E2, or 
prostacyclin on 51cr absorption, retention or urinary 
excretion. 
Hypothesis #1 was rejected because indomethacin 
significantly (p<O.OS) increased chromium absorption. 
Retention of Slcr in tissues was higher (p<O.OS) with 
indomethacin pretreatment. Urinary excretion of 51cr also 
increased significantly (p<O.OS). 
Hypothesis #2 was rejected because, 16, 16-DMPGE2, an 
analogue of prostaglandin E2, significantly reduced 51cr 
absorption and retention in tissues including liver, kidney, 
spleen, heart, testes and bone. Misoprostol, an analogue of 
prostaglandin E1 significantly reduced Slcr absorption. 
--~-'-
Recommendations 
The following recommendations for future research were 
developed from this study. 
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1) Long term studies are needed to investigate the effects 
of extensive use of NSAIDs on the metabolism of 
chromium, since extended use of NSAIDs is quite common 
in patients with arthritis. 
2) Experiments similar to the present experiment should be 
conducted with other analogues of prostaglandins used 
therapeutically to determine their interactions with 
chromium. 
3) Studies should be done with a prostacyclin analogue, 
which would be more stable than prostacyclin. The 
prostacyclin used in the present study appeared to 
degrade after a few days. After the present study was 
completed, leftover prostacyclin was used for a 
different experiment and showed no effect. This would 
indicate that the prostacyclin may have degraded despite 
efforts always to keep it frozen or on ice. 
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